Latest News
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
12 December 2025 - Swedish medical technology company Qlife Holding AB (STO: QLIFE), which develops the Egoo Health at-home diagnostics platform, said on Friday that its system will be used in a performance evaluation study led by Hipro Biotechnology...
BioCryst wins FDA approval for oral HAE prophylaxis in young children
12 December 2025 - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), a US-based biotechnology company focused on treatments for hereditary angioedema (HAE) and other rare diseases, said on Friday that it has received US Food and Drug Administration appr...
Genmab completes tender offer for Merus and opens subsequent offering period
12 December 2025 - Copenhagen-based biotechnology company Genmab A/S (Nasdaq: GMAB) on Friday said that all conditions to its USD97-per-share cash tender offer for Dutch oncology company Merus NV (Nasdaq: MRUS) have been satisfied, enabling acceptanc...
NanOlogy launches drug development program for diffuse intrinsic pontine glioma treatment
12 December 2025 - NanOlogy, LLC, a Texas-based, private clinical-stage oncology company, announced on Thursday that it has launched a drug development program aimed at transforming the treatment of diffuse intrinsic pontine glioma (DIPG), an aggress...
Neurizon Therapeutics' NUZ-001 regimen receives US FDA approval to proceed with the HEALEY ALS Platform Trial
12 December 2025 - Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF), an Australia-based clinical-stage biotech company, announced on Thursday that that the Sean M. Healey & AMG Centre for ALS at Mass General Brigham has received...